Campath-1H and Allogeneic Blood Stem Cell Transplantation for Lymphoid Malignancies
Status:
Terminated
Trial end date:
2006-05-01
Target enrollment:
Participant gender:
Summary
High dose chemotherapy followed by transplantation of allogeneic hematopoietic stem cell with
the use of Campath-1h, a monoclonal antibody that have a synergistic effect to chemotherapy
with minimal toxicity. In addition Campath-1H can improve engraftment of donor cells through
its immunosuppressive properties.